DK2069335T3 - Pyridin-3-ylderivater som immunomoduleringsmidler - Google Patents

Pyridin-3-ylderivater som immunomoduleringsmidler

Info

Publication number
DK2069335T3
DK2069335T3 DK07826286.2T DK07826286T DK2069335T3 DK 2069335 T3 DK2069335 T3 DK 2069335T3 DK 07826286 T DK07826286 T DK 07826286T DK 2069335 T3 DK2069335 T3 DK 2069335T3
Authority
DK
Denmark
Prior art keywords
yld
pyridin
derivatives
immuno modulators
immuno
Prior art date
Application number
DK07826286.2T
Other languages
English (en)
Inventor
Martin Bolli
David Lehmann
Claus Mueller
Oliver Nayler
Boris Mathys
Beat Steiner
Joerg Velker
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK2069335T3 publication Critical patent/DK2069335T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07826286.2T 2006-09-08 2007-09-06 Pyridin-3-ylderivater som immunomoduleringsmidler DK2069335T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006053187 2006-09-08
PCT/IB2007/053593 WO2008029370A1 (en) 2006-09-08 2007-09-06 Pyridin-3-yl derivatives as immunomodulating agents

Publications (1)

Publication Number Publication Date
DK2069335T3 true DK2069335T3 (da) 2013-02-18

Family

ID=38982768

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07826286.2T DK2069335T3 (da) 2006-09-08 2007-09-06 Pyridin-3-ylderivater som immunomoduleringsmidler

Country Status (27)

Country Link
US (1) US8288554B2 (da)
EP (1) EP2069335B1 (da)
JP (1) JP5253400B2 (da)
KR (1) KR101454937B1 (da)
CN (1) CN101522670B (da)
AR (1) AR062684A1 (da)
AU (1) AU2007292992B2 (da)
BR (1) BRPI0716633A2 (da)
CA (1) CA2661315C (da)
CL (1) CL2007002594A1 (da)
CY (1) CY1113858T1 (da)
DK (1) DK2069335T3 (da)
ES (1) ES2400163T3 (da)
HK (1) HK1135976A1 (da)
HR (1) HRP20130180T1 (da)
IL (1) IL197394A (da)
MA (1) MA30717B1 (da)
MX (1) MX2009002234A (da)
MY (1) MY150661A (da)
NO (1) NO20091409L (da)
NZ (1) NZ576059A (da)
PL (1) PL2069335T3 (da)
PT (1) PT2069335E (da)
RU (1) RU2454413C2 (da)
SI (1) SI2069335T1 (da)
TW (1) TWI399371B (da)
WO (1) WO2008029370A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002233A (es) * 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
EP2069335B1 (en) 2006-09-08 2012-12-26 Actelion Pharmaceuticals Ltd. Pyridin-3-yl derivatives as immunomodulating agents
AU2007298593A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
NZ577111A (en) * 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
ES2450750T3 (es) * 2007-03-16 2014-03-25 Actelion Pharmaceuticals Ltd. Derivados de amino-piridina como agonistas del receptor S1P1/EDG1
ES2361463T3 (es) * 2007-08-17 2011-06-17 Actelion Pharmaceuticals Ltd. Derivados de piridina como moduladores del receptor s1p1/edg1.
RU2010121969A (ru) * 2007-11-01 2011-12-10 Актелион Фармасьютиклз Лтд (Ch) Новые производные пиримидина
CA2714614A1 (en) * 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
EP2262799B1 (en) * 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
US8575200B2 (en) * 2008-03-07 2013-11-05 Actelion Pharmaceuticals Ltd Pyridin-2-yl derivatives as immunomodulating agents
NZ588439A (en) * 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
SI2278960T2 (sl) 2008-03-17 2020-02-28 Actelion Pharmaceuticals Ltd. Režim odmerjanja za selektivni agonist receptorja sip1
EP2177521A1 (en) * 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
DE102008063561A1 (de) 2008-12-18 2010-08-19 Bayer Cropscience Ag Hydrazide, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Insektizide
WO2010100142A1 (en) * 2009-03-03 2010-09-10 Merck Serono S.A. Oxazole pyridine derivatives useful as s1p1 receptor agonists
DE102009002514A1 (de) * 2009-04-21 2010-10-28 Evonik Degussa Gmbh Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden
AU2010244930B2 (en) * 2009-05-04 2016-07-28 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical uses thereof
GB0911130D0 (en) * 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
JP2012530728A (ja) * 2009-06-26 2012-12-06 グラクソ グループ リミテッド スフィンゴシン１−リン酸受容体アゴニストとして用いられる５員ヘテロアリール誘導体
AR077413A1 (es) 2009-07-16 2011-08-24 Actelion Pharmaceuticals Ltd Derivados piridin-4-ilo
US8399451B2 (en) * 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US9216972B2 (en) 2009-10-29 2015-12-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
TW201120016A (en) * 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
US8835470B2 (en) 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
US8822510B2 (en) 2010-07-20 2014-09-02 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-Oxadiazole compounds
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
CN103298807A (zh) 2010-11-03 2013-09-11 百时美施贵宝公司 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
DK2665720T3 (da) 2011-01-19 2015-07-13 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl-ylderivater
CA2895172C (en) 2012-08-17 2020-08-18 Actelion Pharmaceuticals Ltd Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process
US9000016B2 (en) 2012-11-05 2015-04-07 Allergan, Inc. 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators
UY35338A (es) 2013-02-21 2014-08-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
PT2970236T (pt) * 2013-03-15 2017-11-30 Idorsia Pharmaceuticals Ltd Derivados de piridin-4-ilo
WO2014176210A1 (en) * 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015073140A1 (en) * 2013-11-14 2015-05-21 Allergan, Inc. 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015108577A1 (en) * 2014-01-15 2015-07-23 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
AR101591A1 (es) 2014-08-20 2016-12-28 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos
HUE047646T2 (hu) 2015-05-20 2020-05-28 Idorsia Pharmaceuticals Ltd Az (S)-3-{4-[5-(2-ciklopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi} -propán-1,2-diol vegyület kristályformája
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
EP3507278B1 (en) 2016-09-02 2021-01-27 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
CA3210658A1 (en) * 2021-02-10 2022-08-18 Icahn School Of Medicine At Mount Sinai Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
WO1991015583A1 (en) 1990-04-05 1991-10-17 The American National Red Cross A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
AU653957B2 (en) 1990-09-20 1994-10-20 Merrell Dow Pharmaceuticals Inc. 1-aryl-3-pyridinyl-2-propene-1-ones
DE4429465A1 (de) 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
WO1999046277A1 (en) 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
DE19904389A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
BR0013427A (pt) 1999-08-19 2002-07-30 Nps Pharma Inc Compostos heteropolicìclicos e seus usos como antagonistas no receptor de glutamato metabotrópico
PL369598A1 (en) 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP2006528980A (ja) 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
EP1670463A2 (en) 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005115382A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
EP2371811B1 (en) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
WO2006100633A1 (en) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS
AU2006226022A1 (en) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
EP1863787B1 (en) 2005-03-23 2011-05-25 Actelion Pharmaceuticals Ltd. Hydogrenated benzo[c]thiophene derivatives as immunomodulators
EP1873153B1 (en) 2005-04-22 2010-07-07 Daiichi Sankyo Company, Limited 3-azetidinecarboxylic acid derivatives for use as immunosuppressants
AU2006239418A1 (en) 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
US20070043104A1 (en) 2005-06-10 2007-02-22 Luthman Ingrid K UII-modulating compounds and their use
BRPI0611631A2 (pt) 2005-06-24 2010-09-21 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
WO2007001973A1 (en) 2005-06-28 2007-01-04 Astrazeneca Ab New use
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
PL1979345T3 (pl) 2006-01-24 2010-04-30 Actelion Pharmaceuticals Ltd Nowe pochodne pirydyny
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
RU2008137553A (ru) 2006-02-21 2010-03-27 Юниверсити Оф Вирджиния Пэтент Фаундейшн (Us) Фенил-циклоалкильные соединения, содержащие гетероциклические структуры
WO2007132307A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
MX2009002233A (es) * 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
EP2069335B1 (en) 2006-09-08 2012-12-26 Actelion Pharmaceuticals Ltd. Pyridin-3-yl derivatives as immunomodulating agents
AU2007298593A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
AU2007302262A1 (en) 2006-09-29 2008-04-03 Novartis Ag Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
UA91793C2 (ru) 2006-10-07 2010-08-25 Смс Зимаг Акциенгезелльшафт Способ эксплуатации конвертера
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20080138955A1 (en) * 2006-12-12 2008-06-12 Zhiyuan Ye Formation of epitaxial layer containing silicon
NZ577111A (en) 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
ES2450750T3 (es) 2007-03-16 2014-03-25 Actelion Pharmaceuticals Ltd. Derivados de amino-piridina como agonistas del receptor S1P1/EDG1
ES2361463T3 (es) 2007-08-17 2011-06-17 Actelion Pharmaceuticals Ltd. Derivados de piridina como moduladores del receptor s1p1/edg1.
RU2010121969A (ru) 2007-11-01 2011-12-10 Актелион Фармасьютиклз Лтд (Ch) Новые производные пиримидина
TW200930363A (en) 2007-12-10 2009-07-16 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
CA2714614A1 (en) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
EP2262799B1 (en) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
NZ588439A (en) 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
US8575200B2 (en) 2008-03-07 2013-11-05 Actelion Pharmaceuticals Ltd Pyridin-2-yl derivatives as immunomodulating agents

Also Published As

Publication number Publication date
HRP20130180T1 (hr) 2013-03-31
SI2069335T1 (sl) 2013-04-30
RU2009112726A (ru) 2010-10-20
PL2069335T3 (pl) 2013-05-31
AU2007292992A1 (en) 2008-03-13
HK1135976A1 (en) 2010-06-18
NZ576059A (en) 2012-03-30
RU2454413C2 (ru) 2012-06-27
AU2007292992B2 (en) 2013-01-10
EP2069335B1 (en) 2012-12-26
NO20091409L (no) 2009-04-07
BRPI0716633A2 (pt) 2013-09-24
MA30717B1 (fr) 2009-09-01
CN101522670B (zh) 2012-05-23
CN101522670A (zh) 2009-09-02
US20100168005A1 (en) 2010-07-01
JP5253400B2 (ja) 2013-07-31
CA2661315A1 (en) 2008-03-13
US8288554B2 (en) 2012-10-16
IL197394A0 (en) 2009-12-24
KR101454937B1 (ko) 2014-10-27
CL2007002594A1 (es) 2008-06-06
CY1113858T1 (el) 2016-07-27
WO2008029370A1 (en) 2008-03-13
EP2069335A1 (en) 2009-06-17
KR20090060327A (ko) 2009-06-11
CA2661315C (en) 2015-11-24
TW200817358A (en) 2008-04-16
IL197394A (en) 2013-08-29
MX2009002234A (es) 2009-03-16
PT2069335E (pt) 2013-03-04
JP2010502694A (ja) 2010-01-28
AR062684A1 (es) 2008-11-26
TWI399371B (zh) 2013-06-21
ES2400163T3 (es) 2013-04-08
MY150661A (en) 2014-02-14

Similar Documents

Publication Publication Date Title
DK2069335T3 (da) Pyridin-3-ylderivater som immunomoduleringsmidler
DK2069336T3 (da) Pyridin-4-yl-derivater som immunomodulerende midler
DK2144897T3 (da) 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DK2300465T3 (da) Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
ES1065655Y (es) Helicoptero
DK1928845T3 (da) Aminodiazepiner som toll-lignende receptor-modulatorer
BRPI0714764A2 (pt) Derivados substituídos de sulfonamida
DK2035549T3 (da) Abcb5-positive mesenkymale stamceller som immunmodulatorer
DK2252609T3 (da) Pyridin-2-yl-derivater som immunomodulerende midler
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
DK2007396T3 (da) Enfumafungin-derivat som antimykotika
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
ATE492529T1 (de) Sulfonamidderivate
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
DE602007001051D1 (de) Projektor
DE112007001949A5 (de) Partnerseitenleuchte
DE602007003121D1 (de) Verpackung
FI7154U1 (fi) Pakkaus
DE602008003432D1 (de) Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren